Quanterix Corporation (QTRX)
NASDAQ:QTRX
Want to see QTRX full AI Analyst Report?
QTRX Stock Chart & Stats
$3.50
-$0.25(-2.12%)
At close: 4:00 PM EST
$3.50
-$0.25(-2.12%)
Day’s Range― - ―
52-Week Range$2.40 - $8.77
Previous CloseN/A
Volume125.22K
Average Volume (3M)509.80K
Market Cap
$142.73M
Enterprise Value$143.30M
Total Cash (Recent Filing)$99.27M
Total Debt (Recent Filing)$35.34M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 10, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding47,105,980
10 Day Avg. Volume461,526
30 Day Avg. Volume509,801
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.92
Price to Sales (P/S)1.96
P/FCF Ratio-3.40
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue0.99
Enterprise Value/Gross Profit2.24
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$4.00Price Target Upside14.29% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.48
Revenue Forecast (FY)$169.93M
Bulls Say, Bears Say
Bulls Say
Installed Base & Market PositionA >2,300 instrument installed base and leadership in ultra‑sensitive immunoassays create durable competitive advantages: they generate recurring consumable demand, enable customer stickiness, and support cross-selling of new assays and upgrades, stabilizing revenue even if instrument sales cycle slowly.
Razor-and-Blades Recurring Revenue ModelThe business model relies on instrument placements to seed high‑margin, repeat consumable purchases and services. That structural pull‑through provides predictable annuity‑like revenue, supports gross margins over time, and aligns incentives to expand installed base and long‑term customer relationships.
Improving Margins, Synergies & LiquidityRealized $85M in run‑rate synergies, sustained ~51% non‑GAAP gross margins and a cash balance near $100M with no debt. These factors materially reduce near‑term refinancing risk, provide runway to invest in commercial and diagnostics initiatives, and improve prospects for reaching cash‑flow breakeven.
Bears Say
Large Ongoing Losses & Cash BurnSustained multi‑hundred‑million dollar losses and consistent negative operating and free cash flow erode equity and heighten funding risk. Over months this limits discretionary investment, increases sensitivity to demand softness, and raises the likelihood the company must access capital markets or dilutive financing if improvements slip.
Material Organic Revenue DeclinesDeep organic declines across core platforms suggest structural end‑market weakness or execution gaps. Lower organic instrument and consumable usage reduces recurring revenue potential and lengthens payback on placements, making margin targets and cash‑flow breakeven dependent on restoring end‑market demand rather than solely cost cuts.
Shareholder Rejection Of Equity PlanDecisive shareholder rejection of the amended equity incentive plan constrains the company's ability to grant equity compensation. That can hinder retention and recruitment of scientific, commercial and executive talent during a critical operational turnaround, potentially increasing cash compensation needs or weakening incentive alignment.
Quanterix News
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $2.40 and its highest was $8.77 in the past 12 months.
What is Quanterix Corporation’s market cap?
Quanterix Corporation’s market cap is $142.73M.
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is Aug 10, 2026 which is in 59 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on May 06, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.513 by $0.143.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Undervalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -0.4.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 47,105,980 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.513. Following the earnings report the stock price went down -16.413%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Currently, no hedge funds are holding shares in QTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quanterix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.00 (14.29% Upside)
$4.00 (14.29% Upside)
Hedge Fund Trend
Increased
By 768.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.83%
12-Months-Change
Fundamentals
Return on Equity
-35.17%
Trailing 12-Months
Asset Growth
-7.53%
Trailing 12-Months
Company Description
Quanterix Corporation
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
QTRX Company Deck
QTRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call mixed encouraging operational and financial progress—an increase in reported revenue, strong non-GAAP gross margins above 50%, delivery of $85M in synergies, a healthy cash balance (~$102.6M), and clear strategic investments in commercial capabilities and diagnostics (HD-X IVD push, Tempus partnership). Offsetting these positives are material organic revenue declines (Simoa -21%, spatial -26%), a 33% drop in pharma revenue, softer-than-expected instrumentation sales, and notable one-time acquisition-related charges. Management maintained full-year guidance and outlined concrete steps to drive H2 improvement and cash-flow breakeven, but near-term execution and end-market recovery remain key risks.View all QTRX earnings summariesQTRX Stock 12 Month Forecast
Average Price Target
$4.00
▲(14.29% Upside)
Technical Analysis
Viemed Healthcare
―
Nano-X Imaging
―
Outset Medical
―
908 Devices
―
TriSalus Life Sciences
―
Ownership Overview
7.05% Insiders
17.87% Mutual Funds
36.89% Other Institutional Investors
27.91% Public Companies and
Individual Investors